Britnae Termara Johnson, in Pittsburg, CA - Behavior Analyst

Britnae Termara Johnson, is a Behavior Analyst based in Pittsburg, California. Britnae Termara Johnson is licensed to practice in * (Not Available) (license number ) and her current practice location is 282 Heron Dr, Pittsburg, California. She can be reached at her office (for appointments etc.) via phone at (925) 238-6482.

NPI number for Britnae Termara Johnson is 1922570175 and her current mailing address is 5820 Stoneridge Mall Rd Ste 205, Pleasanton, California. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1922570175.

Contact Information

	Britnae Termara Johnson,
	282 Heron Dr, Pittsburg, CA 94565-1908
	(925) 238-6482
	Not Available

Healthcare Provider's Profile

Full Name	Britnae Termara Johnson
Gender	Female
Speciality	Behavior Analyst
Location	282 Heron Dr, Pittsburg, California
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1922570175
Provider Enumeration Date: 12/28/2018
Last Update Date: 12/28/2018

Medical Identifiers

Medical identifiers for Britnae Termara Johnson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1922570175	NPI	-	NPPES
10438023	Medicaid	CA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TB0200X	Psychologist - Cognitive & Behavioral	(* (Not Available))	Secondary
103K00000X	Behavior Analyst	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Britnae Termara Johnson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Britnae Termara Johnson, 5820 Stoneridge Mall Rd Ste 205, Pleasanton, CA 94588-3347 Ph: () -	Britnae Termara Johnson, 282 Heron Dr, Pittsburg, CA 94565-1908 Ph: (925) 238-6482

News Archive

Chem Rx reaches asset purchase agreement with PharMerica

Chem Rx Corporation, the third largest long-term care pharmacy in the United States, today announced that it has reached a "stalking horse" asset purchase agreement to sell substantially all of the assets of the company to PharMerica Corporation, an industry-leading pharmaceutical services company serving residents in long-term facilities and settings.

Ending antitrust exemption for insurers may not affect consumers, analysts say

Kaiser Health News: "Proponents say that the legislation would spur competition among insurers and bring down costs for consumers. Reps. Tom Perriello, D-Va., and Betsy Markey, D-Colo., who are sponsoring the bill, said in a press release it would 'end special treatment for the insurance industry that allows them to fix prices, collude with each other, and set their own markets without fear of being investigated.' But many antitrust experts say that ending the exemption - by repealing the 1945 McCarran-Ferguson Act - wouldn't significantly increase competition or reduce premiums."

Early intervention is a critical consideration in efforts to preserve the musculoskeletal system after spinal cord injury

Richard Shields, Ph.D., University of Iowa professor in the Graduate Program in Physical Therapy and Rehabilitation Science, can foresee a time when it might be possible to cure spinal cord injury (SCI).

AmSurg second quarter revenues increase 23% to $231.6 million

Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp., today announced financial results for the second quarter ended June 30, 2012. Revenues for the quarter were $231.6 million, a 23% increase from $187.5 million for the second quarter of 2011.

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

Britnae Termara Johnson, - in Pittsburg, CA